Contributions
Abstract: P725
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Neuro-ophthalmology
Background: Multiple Sclerosis (MS) is a disease characterized by patient reported outcomes (PRO), reported relapses, EDSS with visual acuity, and visible MRI changes. Disease related damage includes both demyelination and axonal injury. People with MS (PwMS) frequently experience visual impairment whether related to optic nerve or cognitive dysfunction in addition to physical/cognitive disability. OCT provides quantitative measures of retinal nerve fiber layer density (RNFL) to quantify axonal damage whereas Visual Evoked Potential latency (VEP-L) provides quantitative measures of demyelination along the optic pathway. RNFL changes have been explored as one objective measure, independent of PRO, EDSS and MRI to identify disease impact/progression in PwMS. The Visual Function Index (VF-14) is a PRO designed to measure the visual function status of patients, providing a vision quality of life index. Visual acuity is a descriptor of a single aspect of vision rather than a comprehensive assessment of perceived visual function. Improved analytics of disease impact capturing both patient perception and objective disease impact would help to better understand treatment efficacy.
Objective: To explore the relationships between VF-14 scores, VEP-L and OCT outcomes in PwMS.
Methods: Retrospective analysis of PwMS who completed both VF-14, VEP and OCT as part of routine care. Analysis was done using linear regression modeling to determine the significance of relationships between VF-14 scores and both VEP and OCT outcomes for each eye. Significance was set at p< 0.05.
Results: 106 PwMS, average age=49.8±12.2 years, 69. 8% female. VF-14 outcome measures were related to OCT Macular Volume (MV) right eye (OD) (p=.024, r=0.22), VF-14 with MV left eye (OS) (p=.017, r=0.23), whereas VF=14 did not track with RNLF (Global OD p=.574 OS p= .454, Asymmetry- p=.39). VF-14 results were also related to VEP-L OS latency (p=.042, r=.19) but not VEP-L OD latency (p=.18).
Conclusions: Visual quality of life as measured by VF-14 scores in PwMS are related to MV but not RNLF. Quantitative measurements of MV by OCT in PwMS should be incorporated into MS care in conjunction with VF-l4 to provide a combination of objective and subjective information regarding disease burden in PwMS. More comprehensive combination of PRO and objective analytics are suggested in addition to reported relapse rate, EDSS, and MRI findings in PwMS to better quantify disease impact and treatment needs.
Disclosure: RJ: Nothing to disclose
JS: Nothing to disclose
AG: Nothing to disclose
LF: Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
CS: Nothing to disclose
JW: Nothing to disclose
DG: Nothing to disclose
Abstract: P725
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Neuro-ophthalmology
Background: Multiple Sclerosis (MS) is a disease characterized by patient reported outcomes (PRO), reported relapses, EDSS with visual acuity, and visible MRI changes. Disease related damage includes both demyelination and axonal injury. People with MS (PwMS) frequently experience visual impairment whether related to optic nerve or cognitive dysfunction in addition to physical/cognitive disability. OCT provides quantitative measures of retinal nerve fiber layer density (RNFL) to quantify axonal damage whereas Visual Evoked Potential latency (VEP-L) provides quantitative measures of demyelination along the optic pathway. RNFL changes have been explored as one objective measure, independent of PRO, EDSS and MRI to identify disease impact/progression in PwMS. The Visual Function Index (VF-14) is a PRO designed to measure the visual function status of patients, providing a vision quality of life index. Visual acuity is a descriptor of a single aspect of vision rather than a comprehensive assessment of perceived visual function. Improved analytics of disease impact capturing both patient perception and objective disease impact would help to better understand treatment efficacy.
Objective: To explore the relationships between VF-14 scores, VEP-L and OCT outcomes in PwMS.
Methods: Retrospective analysis of PwMS who completed both VF-14, VEP and OCT as part of routine care. Analysis was done using linear regression modeling to determine the significance of relationships between VF-14 scores and both VEP and OCT outcomes for each eye. Significance was set at p< 0.05.
Results: 106 PwMS, average age=49.8±12.2 years, 69. 8% female. VF-14 outcome measures were related to OCT Macular Volume (MV) right eye (OD) (p=.024, r=0.22), VF-14 with MV left eye (OS) (p=.017, r=0.23), whereas VF=14 did not track with RNLF (Global OD p=.574 OS p= .454, Asymmetry- p=.39). VF-14 results were also related to VEP-L OS latency (p=.042, r=.19) but not VEP-L OD latency (p=.18).
Conclusions: Visual quality of life as measured by VF-14 scores in PwMS are related to MV but not RNLF. Quantitative measurements of MV by OCT in PwMS should be incorporated into MS care in conjunction with VF-l4 to provide a combination of objective and subjective information regarding disease burden in PwMS. More comprehensive combination of PRO and objective analytics are suggested in addition to reported relapse rate, EDSS, and MRI findings in PwMS to better quantify disease impact and treatment needs.
Disclosure: RJ: Nothing to disclose
JS: Nothing to disclose
AG: Nothing to disclose
LF: Nothing to disclose
MG- Research support (Biogen, EMD Serono, Novartis, Sanofi, Teva); speaker fees/consultant (Acorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Saol Therapeutics, Teva).
MZ- Speaker fees (Acorda, Biogen, Genzyme and Teva)
BB- Speaker fees (Biogen, Genotech, Genzyme and Teva).
MB: Nothing to disclose
CS: Nothing to disclose
JW: Nothing to disclose
DG: Nothing to disclose